Revolution Medicines Inc. (RVMD)
Summary
RVMD Chart
Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan
Revolution Medicines (RVMD) secured rapid FDA approval for RASONQUE, a first-in-class oral RAS(ON) inhibitor targeting metastatic pancreatic cancer. RVMD's multi-selective approach addresses a broad spectrum of RAS mutations, positioning RASONQUE as a potential blockbuster with significant market opportunity. Despite a strong cash position ($3.9B), RVMD will incur substantial losses through 2028, with profitability only projected in 2029 as revenue ramps from global expansion.
Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic Cancer
Revolution Medicines NASDAQ: RVMD said the U.S. Food and Drug Administration has approved daraxonrasib under the brand name RASONQUE for certain adults with metastatic pancreatic adenocarcinoma.
Revolution Medicines, Inc. (RVMD) Discusses FDA Approval of RASONQUE for Metastatic Pancreatic Cancer and Implications for RAS-Driven Therapy Transcript
Revolution Medicines, Inc. (RVMD) Discusses FDA Approval of RASONQUE for Metastatic Pancreatic Cancer and Implications for RAS-Driven Therapy Transcript
Revolution Medicines Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| LC Lisa Candera CIGNA INVESTMENTS Inc. /NEW | 1,774 | $333,000 | $332,678.22 | -$321.78 | -0.1% |
 Curtis Ellergodt Rothschild Investment LLC | 41 | $3,951.51 | $8,089.3 | $4,137.79 | 104.71% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 4,181 | $783,020 | $857,732.11 | $74,712.11 | 9.54% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 79,200 | $10.74M | $16.39M | $5.66M | 52.69% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 198 | $27,648.06 | $40,698.9 | $13,050.84 | 47.2% |
Revolution Medicines Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Robert Driscoll Wedbush | 125.65 | $25,777.69 | $25,830.46 | $52.77 | 0.2% |
| GR Gregory Renza Truist Securities | 19.4 | $2,800.77 | $3,566.87 | $766.1 | 27.35% |
Revolution Medicines Inc. (RVMD) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Revolution Medicines Inc. ever had a stock split?
Revolution Medicines Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mark A. Goldsmith CEO | NASDAQ (NGS) Exchange | 76155X100 CUSIP |
| US Country | 883 Employees | - Last Dividend | - Last Split | 13 Feb 2020 IPO Date |
Overview
Revolution Medicines, Inc. is a clinical-stage company that focuses on precision oncology, specifically targeting RAS-addicted cancers, which are notoriously challenging to treat. The company leverages its expertise in the field to develop innovative therapies designed to inhibit the RAS signaling pathway, a critical driver in many forms of cancer. With a research and development pipeline featuring a variety of RAS(ON) inhibitors and RAS companion inhibitors, Revolution Medicines employs both monotherapy and combination treatment strategies to potentially improve outcomes for patients with these aggressive cancers. Founded in 2014, the company is headquartered in Redwood City, California, positioning itself at the forefront of cancer research with a clear focus on addressing unmet medical needs in the oncology space.
Products and Services
- RMC-6236 (multi): This RAS(ON) inhibitor is currently in phase 1 clinical trial. It exemplifies the company's approach to developing targeted therapies that can be used both as standalone treatments and in combination with other inhibitors or therapeutic agents.
- RMC-6291 (G12C): Also in phase 1 clinical trials, RMC-6291 targets specific mutations within the RAS gene, showcasing Revolution Medicines' commitment to precision oncology by tailoring treatments to the genetic profile of a patient's cancer.
- RMC-9805 (G12D): This development candidate is another example of the company's RAS(ON) inhibitors, focusing on a distinct mutation and currently undergoing phase 1 clinical trials to evaluate its effectiveness and safety.
- Development Candidates (RMC-5127, RMC-0708, RMC-8839): These candidates, including RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), are in various stages of pre-clinical and early clinical development. They represent the next wave of potential treatments targeting a variety of RAS mutations.
- RAS Companion Inhibitors (RMC-4630, RMC-5552):
- RMC-4630 is currently in phase 2 clinical trials. It exemplifies the company's efforts to develop drugs that can be used in combination with their RAS(ON) inhibitors to provide comprehensive treatment solutions.
- RMC-5552 is in phase 1 clinical trial, further expanding the range of the company's portfolio with the goal of offering more effective combination therapy options for patients fighting RAS-addicted cancers.
